Coegin Pharma AB

Coegin Pharma AB has a liquidity position characterized by a current ratio of 1.16, indicating that its current assets slightly exceed its current liabilities. The company holds SEK 7,923,000 in cash and equivalents, which is a significant portion of its total assets of SEK 13,342,000. However, the company's operating cash flow is negative at SEK -16,546,000, and its free cash flow is also negative at SEK -17,593,000, suggesting that it is not generating positive cash from operations. In terms of profitability, Coegin Pharma AB is currently unprofitable, with a net income of SEK -20,497,000 and an operating income of SEK -20,452,000. The company's return on equity is -4.32, and its return on assets is -1.54, both of which are significantly below the industry median for biotechnology firms. These metrics indicate that the company is not effectively utilizing its equity or assets to generate returns. The company's revenue is concentrated in a single business segment, as it does not disclose multiple segments in its financial reporting. Geographically, the company is based in Sweden, and there is no indication of significant international revenue diversification in the provided data. This concentration may expose the company to regional economic and regulatory risks. Looking at the company's growth trajectory, there is no specific outlook provided for the current or next fiscal year in the input data. However, the company's negative operating and net income, along with negative cash flows, suggest that it is in a growth phase that is not yet profitable. The company's capital expenditures are relatively low at SEK -124,000, indicating minimal investment in physical assets. The risk assessment for Coegin Pharma AB indicates a low liquidity risk, as the company has a current ratio above 1 and holds a substantial amount of cash and equivalents. The dilution risk is also assessed as low, with no immediate filing-based liquidity or dilution flags detected. The company's capital structure is debt-free, as indicated by a debt-to-equity ratio of 0.0. This suggests that the company is not leveraging debt to finance its operations, which may limit its growth potential but also reduces financial risk. Recent events and filings do not indicate any significant changes in the company's operations or financial position. The company continues to focus on its core business of developing small molecule therapies and providing consulting services in drug development. There are no indications of major strategic shifts or new product launches in the provided data.